Genetically engineered bacteria for producing lacto-n-neotetraose and construction method and application thereof
By exogenously expressing the Sec signal peptide and glycosyltransferase in genetically engineered bacteria, the partial synthesis of lactose-N-neotetrasaccharide was achieved, solving the problem of low product synthesis efficiency in existing technologies and improving the yield of lactose-N-neotetrasaccharide.
Patent Information
- Application Number
- CN202410913403.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-09
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2044-07-09
AI Technical Summary
Existing biosynthetic methods for lactose-N-neotetrasaccharide suffer from low product synthesis efficiency.
A genetically engineered bacterium was constructed to exogenously express the Sec signal peptide and glycosyltransferases (β-1,3-N-acetylglucosamine transferase and β-1,4-galactosyltransferase), and these were co-expressed in the periplasmic space via the Sec signal peptide to achieve the regional synthesis of intermediate and final products.
The yield of lactose-N-neotetrasaccharide was improved, the expression efficiency of glycosyltransferase was enhanced, and the efficient synthesis of lactose-N-neotetrasaccharide was achieved.
Smart Images

Figure CN118667739B_ABST
Abstract
Description
Technical Field
[0001] This application relates to the field of biotechnology, and in particular to a genetically engineered bacterium that produces lactose-N-neotetrasaccharide, its construction method, and its application. Background Technology
[0002] Human milk oligosaccharides (HMOs) are the third most abundant component of human milk after lactose and fat, and they have important biological functions. Lactose-N-neotetrasaccharide (LNnT) is one of the core components of HMOs and is a Generally Recognized As Safe (GRAS) food additive. It is the second HMO to be commercially added to infant formula after 2'-fucosylated lactose, and it has biological functions such as enhancing human immunity, regulating intestinal flora, and accelerating wound healing.
[0003] Commercial production methods for lactose-N-neotetrasaccharide mainly include chemical synthesis and biosynthesis. Biosynthesis has been achieved using model bacteria such as *Escherichia coli* and *Bacillus subtilis*. Currently, methods for constructing a synthetic pathway for lactose-N-neotetrasaccharide using *E. coli* as a host mainly involve: knocking out the *lacZ* gene in the *E. coli* genome, while simultaneously expressing the β-1,3-N-glucosaminease encoding gene *LgtA* and the β-1,4-galactosyltransferase encoding gene *LgtB*, thereby achieving de novo synthesis of lactose-N-neotetrasaccharide. For example, Zhang Mengwei et al. enhanced the synthesis of UDP-GAL and UDP-GlcNAC by knocking out the lacZ, lacA, nagB, gcd, ugd, wecB, and setA genes in the *E. coli* genome and enhancing the expression of genes such as galU, galEl, gtB, prs, and lacY. CN115851570A describes increasing LNnT production by knocking out the lacZ, wcaJ, and nudD genes in the *E. coli* genome and overexpressing LgtA, galE, and a specific β-1,4-galactosyltransferase gene. However, these methods for the biosynthesis of lactose-N-neotetrasaccharides still have some shortcomings that limit the efficient synthesis of the products.
[0004] Therefore, the traditional biosynthesis methods for lactose-N-neotetrasaccharide still need improvement. Summary of the Invention
[0005] Based on this, one or more embodiments of this application provide a genetically engineered bacterium for producing lactose-N-neotetrasaccharide, its construction method, and its application. The technical solution includes:
[0006] According to a first aspect of the embodiments of this application, a genetically engineered bacterium that produces lactose-N-neotetrasaccharide is provided, wherein the genetically engineered bacterium expresses exogenous:
[0007] (1) Sec signal peptide; and
[0008] (2) Glycosyltransferases, including β-1,3-N-acetylglucosamine transferase and β-1,4-galactosyltransferase.
[0009] In one embodiment, the Sec signal peptide is linked to the N-terminus of the β-1,3-N-acetylglucosamine transferase, and the two are co-expressed.
[0010] In one embodiment, the Sec signal peptide is linked to the N-terminus of the β-1,4-galactosyltransferase, and the two are co-expressed.
[0011] In one embodiment, the Sec signal peptide includes one or more of the following: DsbA signal peptide, DacD signal peptide, OmpA signal peptide, pelB signal peptide, MalE signal peptide, LamB signal peptide, and FadL signal peptide.
[0012] In one embodiment, one or more of the following conditions are met:
[0013] (1) The nucleotide sequence encoding the pelB signal peptide is shown in SEQ ID NO:1 or SEQ ID NO:2;
[0014] (2) The nucleotide sequence encoding the DsbA signal peptide is shown in SEQ ID NO:3; and
[0015] (3) The nucleotide sequence encoding the OmpA signal peptide is shown in SEQ ID NO:4.
[0016] In one embodiment, the glycosyltransferase satisfies one or more of the following conditions:
[0017] (1) The nucleotide sequence encoding β-1,3-N-acetylglucosamine transferase is shown in SEQ ID NO:5; and
[0018] (2) The nucleotide sequence encoding β-1,4-galactosyltransferase is shown in SEQ ID NO:6.
[0019] In one embodiment, the genetically engineered bacteria include bacteria;
[0020] Optionally, the bacteria include one or more of Escherichia coli and Bacillus subtilis;
[0021] Optionally, one or more of the wcaJ gene, lacZ gene, fucIK gene, nanA gene, nanK gene, nanE gene, and nanT gene in the genome of the genetically engineered bacteria are inactivated or deleted.
[0022] Further, optionally, the wcaJ gene, lacZ gene, and fucIK gene in the genome of the genetically engineered bacteria are inactivated or deleted.
[0023] According to a second aspect of the embodiments of this application, a method for constructing a genetically engineered bacterium that produces lactose-N-neotetrasaccharide as described in any of the above claims is provided, comprising the following steps:
[0024] The nucleic acid fragment encoding the Sec signal peptide and the glycosyltransferase was introduced into the chassis cells to construct the genetically engineered bacteria.
[0025] According to a third aspect of the embodiments of this application, a method for preparing lactose-N-neotetrasaccharide is provided, comprising the following steps:
[0026] Fermentation culture of any of the above-mentioned genetically engineered bacteria to prepare lactose-N-neotetrasaccharide.
[0027] According to a fourth aspect of the embodiments of this application, a method for producing dairy products is provided, comprising the following steps:
[0028] Lactose-N-neotetrasaccharide was prepared using the above-described preparation method; and,
[0029] Dairy products are prepared using the lactose-N-neotetrasaccharide.
[0030] Compared with traditional technologies, this application has the following advantages:
[0031] The applicant of this application discovered through extensive research that by simultaneously transferring the coding fragments of the Sec signal peptide and the glycosyltransferases (β-1,3-N-acetylglucosamine transferase and β-1,4-galactosyltransferase) required for the lactose-N-neotetrasaccharide synthesis pathway into genetically engineered bacteria, the Sec signal peptide and one of the glycosyltransferases are co-expressed and secreted into the periplasmic space, thereby enhancing the expression efficiency of the protein. At the same time, the intermediate and final products of the lactose-N-neotetrasaccharide synthesis pathway are synthesized in separate regions, ultimately improving the yield of lactose-N-neotetrasaccharide. Attached Figure Description
[0032] To more clearly illustrate the technical solutions in the specific embodiments of this application or the prior art, the drawings used in the description of the specific embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are some embodiments of this application. For those skilled in the art, other drawings can be obtained from these drawings without creative effort.
[0033] Figure 1This is a plasmid map of the recombinant plasmid pRSFDuet-pelB-LgtALgtB constructed in Example 1 of this application. Detailed Implementation
[0034] To make the above-mentioned objectives, features, and advantages of this application more apparent and understandable, a detailed description of specific embodiments of this application is provided. Many specific details are set forth in the following description to provide a thorough understanding of this application. However, this application can be implemented in many other ways different from those described herein, and those skilled in the art can make similar modifications without departing from the spirit of this application. Therefore, this application is not limited to the specific embodiments disclosed below.
[0035] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs. The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the application. Unless otherwise specifically stated, all raw materials, reagents, instruments, and equipment used in this application are commercially available or can be prepared by existing methods.
[0036] The terms "and / or," "or / and," and "and / or" as used herein include any one of two or more of the related listed items, as well as any and all combinations of the related listed items. These arbitrary and all combinations include any two related listed items, any more related listed items, or a combination of all related listed items. It should be noted that when at least three items are connected by at least two conjunctions selected from "and / or," "or / and," and "and / or," it should be understood that in this application, the technical solution undoubtedly includes technical solutions connected by "logical AND," and also undoubtedly includes technical solutions connected by "logical OR." For example, "A and / or B" includes three parallel solutions: A, B, and A+B. For example, the technical solution of "A, and / or, B, and / or, C, and / or, D" includes any one of A, B, C, and D (that is, a technical solution that is connected by "logical OR"), as well as any and all combinations of A, B, C, and D, that is, combinations of any two or three of A, B, C, and D, and also combinations of all four of A, B, C, and D (that is, a technical solution that is connected by "logical AND").
[0037] In this application, the terms "multiple", "various", "multiple times", "multi-dimensional", etc., unless otherwise specified, refer to a quantity greater than or equal to 2. For example, "one or more" means one or more than or equal to two.
[0038] In this application, terms such as "further," "even further," and "particularly" are used to describe purposes and indicate differences in content, but should not be construed as limiting the scope of protection of this application.
[0039] In this application, "optionally," "optionally," and "optional" mean that something is optional, that is, it means that it is selected from either "with" or "without." If there are multiple "optional" entries in a technical solution, unless otherwise specified, and there are no contradictions or mutual constraints, each "optional" entry shall be independent.
[0040] In this application, the technical features described in an open-ended manner include both closed technical solutions consisting of the listed features and open technical solutions that include the listed features.
[0041] In this application, numerical intervals (i.e., numerical ranges) are involved. Unless otherwise specified, the selected numerical distributions within the aforementioned numerical intervals are considered continuous and include the two endpoints (i.e., the minimum and maximum values) of the numerical range, as well as every value between these two endpoints. Unless otherwise specified, when a numerical interval refers only to integers within that interval, it includes the two endpoint integers of the numerical range, as well as every integer between the two endpoints. In this document, this is equivalent to directly listing every integer. For example, if t is an integer selected from 1 to 10, it means that t is any integer selected from the group of integers consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10. Furthermore, when multiple ranges are provided to describe features or characteristics, these ranges can be merged. In other words, unless otherwise specified, the ranges disclosed herein should be understood to include any and all subranges to which they are included.
[0042] In this application, the terms "first aspect," "second aspect," "third aspect," "fourth aspect," etc., are used for descriptive purposes only and should not be construed as indicating or implying relative importance or quantity, nor should they be construed as implicitly indicating the importance or quantity of the indicated technical features. Moreover, "first," "second," "third," "fourth," etc., serve only as a non-exhaustive enumeration and should be understood not to constitute a closed limitation on quantity.
[0043] Unless otherwise specified, the temperature parameters in this application are permitted to be either constant-temperature treatment or variations within a certain temperature range. It should be understood that the constant-temperature treatment allows temperature fluctuations within the precision range of the instrument control, such as ±5℃, ±4℃, ±3℃, ±2℃, or ±1℃.
[0044] All references to documents mentioned in this application are incorporated herein by reference as if each document were individually incorporated by reference. Unless they conflict with the inventive purpose and / or technical solution of this application, all cited documents are incorporated herein by reference in their entirety and for all purposes. When citing documents in this application, the definitions of relevant technical features, terms, nouns, phrases, etc., are also incorporated herein by reference. When citing documents in this application, examples and preferred embodiments of the cited technical features may also be incorporated herein by reference, but only to the extent that they enable the implementation of this application. It should be understood that when the cited content conflicts with the description in this application, this application shall prevail or modifications shall be made adaptably to the description in this application.
[0045] In this application, the terms "homology," "identity," and "similarity" are used interchangeably. "Homology," "identity," and "similarity" refer to the fact that two or more sequences share the same bases or amino acid residues at specific percentages of corresponding positions when comparisons and alignment pairwise relationships are maximized. The identity of nucleotide sequences can be determined using homology search sites on the Internet, such as the BLAST page on the NCBI homepage. Alignment percentage homology or identity can be determined using any suitable software program known in the art, for example, as described in Current Protocols in Molecular Biology (FMAusubel, et al., (eds) 1987, Supplement 30, section 7.7.18). Optional procedures include the GCGPileup procedure, such as FASTA (Pearson, et al., 1988 Proc. Natl. Acad. Sci. USA 85:2444-2448) and BLAST (B LASTManual, Altschul et al.. Natl. Cent Biotechnol. linf.. NatLibMed. (NCIB NLM NIH), Bethesda, Md.. and Altschul et al., 1997 NAR25:3389-3402). Another optional alignment procedure is ALIGN Plus (Scientific and Educational Software, PA), which preferably uses basic parameters. Another optional sequence software program that can be used here is the TFASTA data search program used in Sequence Software Package version 6.0 (Genetics Computer Group, University of Wisconsin, Madison W). Examples of commonly used sequence alignment algorithms include, but are not limited to, CLUSTAL Omega, EMBOSS Needle, MAFFT, or MUSCLE.
[0046] According to the first aspect of this application, a genetically engineered bacterium that produces lactose-N-neotetrasaccharide is provided, wherein the exogenous expression is:
[0047] (1) Sec signal peptide; and
[0048] (2) Glycosyltransferases, including β-1,3-N-acetylglucosamine transferase and β-1,4-galactosyltransferase.
[0049] This application does not impose any particular limitation on the order in which the coding fragments of the Sec signal peptide and the coding fragments of glycosyltransferase are linked in genetically engineered bacteria. For example, the exogenously expressed Sec signal peptide in genetically engineered bacteria can be linked to the N-terminus of β-1,3-N-acetylglucosamine transferase or to the N-terminus of β-1,4-galactosyltransferase. Linking the Sec signal peptide to one of these glycosyltransferases allows for co-expression, thereby transferring it into the periplasmic space and enabling the regional synthesis of intermediate and final products.
[0050] In some specific examples, the Sec signal peptide is linked to the N-terminus of β-1,3-N-acetylglucosamine transferase and the two are co-expressed.
[0051] In some specific examples, the Sec signal peptide is linked to the N-terminus of β-1,4-galactosyltransferase and the two are co-expressed.
[0052] This application does not impose any particular limitation on the connection mode of β-1,3-N-acetylglucosamine transferase and β-1,4-galactosyltransferase in genetically engineered bacteria.
[0053] In this application, the coding fragments of the Sec signal peptide and one of the glycosyltransferases are integrated into the same expression vector for co-transcription. Furthermore, the coding fragments of β-1,3-N-acetylglucosamine transferase and β-1,4-galactosyltransferase can be integrated independently into different expression vectors or into the same expression vector.
[0054] The general secrecy pathway (Sec) is a crucial pathway regulating protein transport and secretion, widely present in various cell types. Signal peptides dependent on the Sec secretion pathway (referred to as "Sec signal peptides" in this application) guide the transmembrane transport of newly synthesized proteins into the periplasmic space. During transmembrane transport, the signal peptide is cleaved by signal peptidase, resulting in the mature protein. The periplasmic space, also known as the periplasmic or cell wall space, generally refers to the narrow space (approximately 12 nm–15 nm wide) between the outer membrane and cell wall in bacteria, and is gelatinous in nature.
[0055] In some embodiments, the Sec signal peptide includes one or more of the following: DsbA signal peptide, DacD signal peptide, OmpA signal peptide, pelB signal peptide, MalE signal peptide, LamB signal peptide, and FadL signal peptide.
[0056] In some specific examples, the nucleotide sequence encoding the pelB signal peptide is as shown in SEQ ID NO:1 or SEQ ID NO:2. In other specific examples, the nucleotide sequence encoding the pelB signal peptide has at least 80% homology with SEQ ID NO:1 or SEQ ID NO:2. For example, the nucleotide sequence encoding the pelB signal peptide has 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% homology with SEQ ID NO:1 or SEQ ID NO:2.
[0057] Specifically, the nucleotide sequence shown in SEQ ID NO:1 is as follows:
[0058] 5'-aaatacctgctgccgaccgctgctgctggtctgctgctcctcgctgcccagccggcgatggcc-3'.
[0059] The nucleotide sequence shown in SEQ ID NO:2 is as follows:
[0060] 5'-aaatatttactacccacagcagctgcgggtttgctattattggcggctcagccggctatggcc-3'.
[0061] In some specific examples, the nucleotide sequence encoding the DsbA signal peptide is shown in SEQ ID NO:3. In other specific examples, the nucleotide sequence encoding the DsbA signal peptide has at least 80% homology with SEQ ID NO:3. For example, the nucleotide sequence encoding the DsbA signal peptide has 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% homology with SEQ ID NO:3. Specifically, the nucleotide sequence shown in SEQ ID NO:3 is:
[0062] 5'-atgaaaaaaatttggctggcgctggcgggcctggtgctggcgtttagcgcgagcgcg-3'.
[0063] In some specific examples, the nucleotide sequence encoding the OmpA signal peptide is shown in SEQ ID NO:4. In other specific examples, the nucleotide sequence encoding the OmpA signal peptide has at least 80% homology with SEQ ID NO:4. For example, the nucleotide sequence encoding the pelB signal peptide has 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% homology with SEQ ID NO:4.
[0064] Specifically, the nucleotide sequence shown in SEQ ID NO:4 is as follows:
[0065] 5'-atgaaaaaaaccgcgattgcgattgcggtggcgctggcgggctttgcgaccgtggcgcaggcg-3'.
[0066] Understandably, β-1,3-N-acetylglucosamine transferase and β-1,4-galactosyltransferase are two key glycosyltransferases in the lactose-N-neotetrasaccharide synthesis pathway. β-1,3-N-acetylglucosamine transferase catalyzes the transfer of N-acetylglucosamine (GlcNAc) derived from uridine-5'-bisphosphate-GlcNAc (UDP-GlcNAc) to the 3'-OH position at the end of an N-acetyllactosamine derivative, forming an N-acetyllactosamine polysaccharide chain; it can synthesize lactose-N-trisaccharide II (LNT II) using lactose as the acceptor and GlcNAc as the donor. β-1,4-galactosyltransferase (β-1,4-GalT) catalyzes the transfer of galactosyl groups from lactose to lactose-N-trisaccharide II, and synthesizes lactose-N-neotetrasaccharide using UDP-galactose and lactose-N-trisaccharide II as substrates.
[0067] This application does not specifically limit the source of β-1,3-N-acetylglucosamine transferase; a suitable β-1,3-N-acetylglucosamine transferase can be selected as needed. As an example, β-1,3-N-acetylglucosamine transferase LgtA derived from Neisseria meningitidis MC58 can be used. Understandably, when lactose is used as the acceptor, β-1,3-N-acetylglucosamine transferases from meningococci have a broad acceptor spectrum, and their activity can reach more than 75 times that of transferases derived from mammals.
[0068] In some specific examples, the nucleotide sequence encoding β-1,3-N-acetylglucosamine transferase is as shown in SEQ ID NO:5; or has at least 80% homology with the nucleotide sequence shown in SEQ ID NO:5. For example, it has 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% homology.
[0069] This application does not impose any particular limitation on the source of β-1,4-galactosyltransferase; a suitable β-1,4-galactosyltransferase can be selected as needed. For example, β-1,4-galactosyltransferase LgtB derived from Helicobacter pylori can be used.
[0070] In some specific examples, the nucleotide sequence encoding β-1,4-galactosyltransferase is as shown in SEQ ID NO:6; or has at least 80% homology with the nucleotide sequence shown in SEQ ID NO:6. For example, it has 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% homology.
[0071] The genetically engineered bacteria described in this application can be any host cell commonly used in the art, and there are no particular limitations. Host cells include prokaryotic and / or eukaryotic cells. In some optional examples, they can be bacterial or yeast cells, such as *Escherichia coli*, *Bacillus subtilis*, etc.; in other optional examples, they can be eukaryotic cells, such as yeast cells, plant cells, insect cells, and animal cells, such as mammalian cells (e.g., mouse cells, human cells, etc.). For bacterial host cells, there are no limitations in principle; they can be eubacteria (Gram-positive or Gram-negative bacteria) or archaea, as long as they allow for the insertion of the gene of interest for genetic modification and can be cultured on a production scale.
[0072] For example, bacteria could be *Escherichia coli*, *Klebsiella oxytoca*, *Anaerobiospirillum succiniciproducens*, *Actinobacillus succinogenes*, *Mannheimia succiniciproducens*, *Rhizobium etli*, *Bacillus subtilis*, *Bacillus methanolicus*, *Corynebacterium glutamicum*, *Gluconobacter oxydans*, *Zymomonas mobilis*, *Lactococcus lactis*, *Lactobacillus plantarum*, and *Streptomyces*. The bacteria are *Clostridium acetobutylicum*, *Pseudomonas fluorescens*, or *Pseudomonas putida*.
[0073] For example, yeasts or fungi could be Saccharomyces cerevisiae, Schizosaccharomyces pombe, Kluyveromyces lactis, Kluyveromyces marxianus, Aspergillus terreus, Aspergillus niger, Pichiapastoris, Rhizopusarrhizus, or Yarrowialipolytica, etc.
[0074] In some specific examples, the genetically engineered bacterium is *Escherichia coli*; the *Escherichia coli* can be *Escherichia coli* BL21(DE3) or *Escherichia coli* MG1655. Optionally, it is *Escherichia coli* BL21(DE3).
[0075] In some specific examples, the genome of genetically engineered bacteria includes one or more of the following genes: wcaJ, lacZ, fucIK, and nanAKET. For instance, the genome of genetically engineered bacteria may include one, two, three, or more of the following genes: wcaJ, lacZ, fucIK, and nanAKET.
[0076] For example, the genetically engineered bacteria can be BL21(DE3)ΔwcaJ, BL21(DE3)ΔlacZ, BL21(DE3)ΔfucIK, BL21(DE3)ΔwcaJΔlacZ, BL21(DE3)ΔwcaJΔfucIK, BL21(DE3)ΔlacZΔfucIK, or BL21(DE3)ΔwcaJΔlacZΔfucIK.
[0077] Among them, the wcaJ gene encodes UDP-glucose lipotransferase, and its inactivation or deletion can prevent the capsular heteropolysaccharide metabolic synthesis pathway, thereby increasing the accumulation of the precursor UDP-galactose; the lacZ gene encodes β-galactosidase, and its inactivation or deletion can prevent lactose from being degraded into glucose and galactose; the fucI and fucK genes encode L-fucose isomerase and L-fucokinase, respectively, and their inactivation or deletion can prevent L-fucose from entering the glycolysis pathway; the nanA gene encodes N - Acetylmannosamine lyase, inactivation or deletion of which can prevent the degradation of N-acetylneuraminic acid and N-acetylmannosamine; nanK gene encodes N-acetylmannosamine kinase, inactivation or deletion of which can prevent the degradation of N-acetylmannosamine-6-phosphate; nanE gene encodes N-acetylmannosamine-6-phosphate-2-epimerase, inactivation or deletion of which can prevent the degradation of glucosamine-6-phosphate; nanT gene encodes sialic acid transporter, inactivation or deletion of which can prevent the intracellular and extracellular transport of sialic acid.
[0078] Understandably, in this application, "inactivation" means that the relevant gene is not expressed or its expression activity is reduced; "deletion" means that all or part of the coding segment of the relevant gene is missing; this application does not particularly limit the manner of gene inactivation and gene deletion, and any method commonly used in the art can be used.
[0079] In some specific examples, the genome of genetically engineered bacteria may also contain one or more of the following genes that are inactivated or deleted: lacA, nagB, gcd, ugd, wecB, and setA.
[0080] In some specific examples, the genome of the genetically engineered bacteria may also contain one or more of the following genes with enhanced expression: lacY, prs, glmU, glmM, glmS, pgm, galU, galE, and gtB.
[0081] Understandably, the genetically engineered bacteria in this application can be either modified chassis cells or unmodified chassis cells, as long as they can achieve the technical effects of this application. For example, the genetically engineered bacteria in this application can be selected from various types of chassis cells that have already been modified in conventional techniques.
[0082] In some specific examples, the genome of the genetically engineered bacteria also includes expression regulatory elements such as promoters, enhancers, and terminators to improve gene expression levels, expression efficiency, product activity, and other performance aspects. Any promoter, enhancer, and terminator known in the art can be applied to the genetically engineered bacteria of this application, as long as it can achieve the technical effects of this application. As an example, the promoter can be the T7 promoter.
[0083] In some specific examples, the genome of genetically engineered bacteria also includes endogenous nucleic acid fragments, including nucleic acid molecules that have been modified but not removed from the strain; the modifications include, but are not limited to, gene substitution, site-specific mutations, etc.
[0084] In some specific examples, the nucleic acid fragments encoding the Sec signal peptide and / or glycosyltransferase in the genetically engineered bacteria can be single copies or multiple copies.
[0085] The genetically engineered bacteria of this application can exogenously express the Sec signal peptide and the transferases required in the synthesis pathway of lactose-N-neotetrasaccharide. Therefore, when using the above-mentioned genetically engineered bacteria to ferment and culture lactose-N-neotetrasaccharide, the Sec signal peptide can transport either β-1,3-N-acetylglucosamine transferase or β-1,4-galactosyltransferase to the periplasmic space, thereby enabling the synthesis of lactose-N-trisaccharide II or lactose-N-neotetrasaccharide in the periplasmic space, while other substances are synthesized intracellularly. The genetically engineered bacteria of this application can increase the expression efficiency of related glycosyltransferases in the periplasmic space and achieve regional synthesis of lactose-N-neotetrasaccharide and lactose-N-trisaccharide II, ultimately improving the fermentation yield of lactose-N-neotetrasaccharide.
[0086] According to a second aspect of this application, a method for constructing the genetically engineered bacteria described in the first aspect is provided, comprising the following steps:
[0087] Nucleic acid fragments encoding the Sec signal peptide, β-1,3-N-acetylglucosamine transferase, and β-1,4-galactosyltransferase were introduced into chassis cells to construct genetically engineered bacteria.
[0088] In some specific examples, the method for constructing the above-mentioned genetically engineered bacteria includes the following steps S10 to S30:
[0089] S10 provides nucleic acid fragments encoding the Sec signal peptide and glycosyltransferase, respectively;
[0090] S20. Construct an expression vector containing the above-mentioned nucleic acid fragments; and,
[0091] S30. Transform the expression vector constructed in step S20 into chassis cells to construct genetically engineered bacteria.
[0092] In some specific examples, the nucleic acid fragments encoding the Sec signal peptide and the glycosyltransferase are as defined in the first aspect.
[0093] Optionally, the Sec signal peptide includes one or more of the following: DsbA signal peptide, DacD signal peptide, OmpA signal peptide, pelB signal peptide, MalE signal peptide, LamB signal peptide, and FadL signal peptide.
[0094] Further optionally, the nucleotide sequence encoding the Sec signal peptide is as shown in any one of SEQ ID NO:1 to 4, or has at least 80% (e.g., 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) homology with the nucleotide sequence shown in any one of SEQ ID NO:1 to 4.
[0095] Optionally, the glycosyltransferase includes β-1,3-N-acetylglucosamine transferase and β-1,4-galactosyltransferase.
[0096] Further optionally, the nucleic acid fragment encoding the glycosyltransferase includes the nucleotide sequence shown in SEQ ID NO:5 and SEQ ID NO:6, or includes a nucleotide sequence having at least 80% (e.g., 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) homology with the nucleotide sequence shown in SEQ ID NO:5 and SEQ ID NO:6.
[0097] This application does not impose any particular limitation on the type of expression vector, which can be any vector commonly used in the art, such as, but not limited to, pRSFDuet-1 plasmid or pSL plasmid. This application also does not impose any particular limitation on the construction method of the expression vector, which can be any method commonly used in the art, such as double enzyme digestion or homologous recombination.
[0098] In some specific examples, the coding fragments for the Sec signal peptide and at least one of the glycosyltransferases are integrated into the same expression vector for co-transcription. Furthermore, the coding fragments for β-1,3-N-acetylglucosamine transferase and β-1,4-galactosyltransferase can be integrated independently into different expression vectors or into the same expression vector.
[0099] In this application, the method for transforming the expression vector into chassis cells is not particularly limited, as long as it can transform the recombinant expression vector into chassis cells. The transformation method includes, but is not limited to, heat shock method, electroporation method, calcium ion method and protoplast method.
[0100] According to a third aspect of this application, a method for preparing lactose-N-neotetrasaccharide is provided, comprising the following steps:
[0101] The genetically engineered bacteria of the first aspect of this application were fermented to prepare lactose-N-neotetrasaccharide.
[0102] Specifically, in the first aspect of this application, the genetically engineered bacteria exogenously express Sec signal peptide and glycosyltransferase, the glycosyltransferase including β-1,3-N-acetylglucosamine transferase and β-1,4-galactosyltransferase.
[0103] Optionally, the Sec signal peptide includes one or more of the following: DsbA signal peptide, DacD signal peptide, OmpA signal peptide, pelB signal peptide, MalE signal peptide, LamB signal peptide, and FadL signal peptide.
[0104] Further optionally, the nucleotide sequence encoding the pelB signal peptide is as shown in SEQ ID NO:1 or SEQ ID NO:2, or has at least 80% (e.g., 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) homology with the nucleotide sequence shown in SEQ ID NO:2; the nucleotide sequence encoding the DsbA signal peptide is as shown in SEQ ID NO:3, or has at least 80% (e.g., 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) homology with the nucleotide sequence shown in SEQ ID NO:3; the nucleotide sequence encoding the OmpA signal peptide is as shown in SEQ ID NO:4, or has at least 80% (e.g., 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) homology with the nucleotide sequence shown in SEQ ID NO:2; The nucleotide sequence shown in NO:4 has at least 80% (e.g., 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) homology.
[0105] Optionally, the nucleotide sequence encoding β-1,3-N-acetylglucosamine transferase is as shown in SEQ ID NO:5 or has at least 80% (e.g., 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) homology with SEQ ID NO:5.
[0106] Optionally, the nucleotide sequence encoding β-1,4-galactosyltransferase is as shown in SEQ ID NO:6 or has at least 80% (e.g., 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) homology with SEQ ID NO:6.
[0107] In some embodiments, the fermentation culture temperature is 36°C to 38°C. For example, it can be 36°C, 36.1°C, 36.2°C, 36.3°C, 36.4°C, 36.5°C, 36.6°C, 36.7°C, 36.8°C, 36.9°C, 37°C, 37.1°C, 37.2°C, 37.3°C, 37.4°C, 37.5°C, 37.6°C, 37.7°C, 37.8°C, 37.9°C, or 38°C.
[0108] In some embodiments, the fermentation time is 65 h to 80 h. For example, it can be 65 h, 66 h, 67 h, 68 h, 69 h, 70 h, 71 h, 72 h, 73 h, 74 h, 75 h, 76 h, 77 h, 78 h, 79 h, or 80 h.
[0109] Understandably, the fermentation culture methods include, but are not limited to, the specific methods described above, and may also include other fermentation culture methods commonly used in this field.
[0110] In some embodiments, the fermentation culture medium comprises the following components: 3.8 g / L to 4.2 g / L diammonium hydrogen phosphate, 13 g / L to 14 g / L potassium dihydrogen phosphate, 18 g / L to 22 g / L glycerol, 1.6 g / L to 1.8 g / L citric acid, 3.5 g / L to 4.5 g / L yeast extract, 1.2 g / L to 1.6 g / L manganese sulfate heptahydrate, 4 g / L to 6 g / L lactose, and IPTG at a final concentration of 0.18 mM to 0.22 mM.
[0111] Understandably, the types of fermentation media are not limited to those mentioned above, and may also include other fermentation media commonly used in this field.
[0112] In one specific example, the fermentation culture medium includes the following components: 4 g / L diammonium hydrogen phosphate, 13.5 g / L potassium dihydrogen phosphate, 20 g / L glycerol, 1.7 g / L citric acid, 4 g / L yeast extract, 1.4 g / L manganese sulfate heptahydrate, 5 g / L lactose, and IPTG at a final concentration of 0.2 mM.
[0113] In some embodiments, prior to fermentation culture of the genetically engineered bacteria, the following step is included: activating the genetically engineered bacteria at least once. Understandably, the activation culture may be performed once, twice, three times, or more.
[0114] In some specific examples, the medium used for activation culture is LB liquid medium.
[0115] In some specific examples, the activation culture temperature is 36℃~38℃. For example, it can be 36℃, 36.1℃, 36.2℃, 36.3℃, 36.4℃, 36.5℃, 36.6℃, 36.7℃, 36.8℃, 36.9℃, 37℃, 37.1℃, 37.2℃, 37.3℃, 37.4℃, 37.5℃, 37.6℃, 37.7℃, 37.8℃, 37.9℃, or 38℃.
[0116] According to a fourth aspect of this application, a method for producing dairy products is provided, comprising the following steps:
[0117] Lactose-N-neotetrasaccharide was prepared using the method described in the third aspect above; and,
[0118] Dairy products are prepared using lactose-N-neotetrasaccharide.
[0119] Specifically, the detailed steps of the preparation method of lactose-N-neotetrasaccharide are as defined in the third aspect of this application, which includes the following steps: fermenting and culturing the genetically engineered bacteria of the first aspect of this application to prepare lactose-N-neotetrasaccharide.
[0120] Understandably, the method for preparing dairy products using lactose-N-neotetrasaccharide can be any method commonly used in the art, and this application does not impose any particular limitation.
[0121] The present application will be further described below with reference to specific embodiments and comparative examples, but these should not be construed as limiting the scope of protection of the present application. Unless otherwise specified, the raw materials involved in the following specific embodiments are all commercially available, the instruments used are all commercially available, and the processes involved are conventionally selected by those skilled in the art unless otherwise specified.
[0122] Example 1: Construction of recombinant strain pRSFDuet-pelB-LgtALgtB-BL21(DE3)
[0123] (1) Gene synthesis: The gene encoding β-1,3-acetylglucosamine transferase LgtA (nucleotide sequence as shown in SEQ ID NO:5) from Neisseria meningitidis MC58 was synthesized; the gene encoding β-1,4-galactosyltransferase LgtB (nucleotide sequence as shown in SEQ ID NO:6) from Helicobacter pylori was synthesized; and the gene fragment encoding the pelB signal peptide protein (nucleotide sequence as shown in SEQ ID NO:1) was synthesized.
[0124] SEQ ID NO:1
[0125] aaatacctgctgccgaccgctgctgctggtctgctgctcctcgctgcccagccggcgatggcc。
[0126] SEQ ID NO:5
[0127]
[0128] SEQ ID NO:6
[0129] atgcgtgtttttatcatcagcctgaatcagaaagtttgcgatacctttggcctggtgtttcgcgataccaccaccctgctgaataatattaatgccacccatcatcaggcacagatttttgatgcaatttatagtaagaccttcgaaggtggtctgcatccgctggtgaaaaaacatctgcatccgtattttattacccagaatattaaggatatgggcattaccaccaatctgattagtgaagttagcaaattttactacgcactgaaatatcatgcaaaatttatgagtctgggcgaactgggttgttatgccagccattatagcctgtgggaaaaatgtattgaactgaatgaagccatttgtattctggaagatgatattaccctgaaagaagattttaaggaaggcctggattttctggaaaaacatattcaggaactgggctatgtgcgtctgatgcatctgctgtatgatccgaatgttaaaagtgaaccgctgaatcataaaaatcatgaaattcaggagcgcgttggcattattaaagcatatagccatggtgttggcacccagggttatgttattaccccgaaaattgcaaaagtttttaagaaacacagccgcaaatgggtggtgccggttgataccattatggatgccacctttattcatggcgttaaaaatctggtgctgcagccgtttgtgattgcagatgatgaacagattagcaccattgcacgtaaagaagaaccgtatagcccgaaaattgccctgatgcgtgaactgcattttaaatatctgaaatactggcagttcgtgtaa。
[0130] (2) Construction of recombinant plasmid:
[0131] (a) The pRSFDuet-1 vector (purchased from Addgene's official website) and the fragment amplified using LgtA as a template in step (1) were double-digested using BamH I restriction endonuclease and Not I restriction endonuclease. The digested fragments were ligated using T4 ligase and transformed into Escherichia coli DH5α. Positive transformants were screened, verified, and sequenced to obtain the plasmid pRSFDuet-LgtA.
[0132] The amplification primer sequences for fragment LgtA are shown in SEQ ID NO:7~8.
[0133] SEQ ID NO: 7 (LgtA-F): cgggatccgatgccgagcgaagcc.
[0134] SEQ ID NO: 8 (LgtA-R): ataagaatgcggccgcttagcgatttttcagcaggcg.
[0135] The amplification primer sequences used for verification and sequencing are shown in SEQ ID NO:9~10.
[0136] SEQ ID NO: 9 (LgtA-YZ-F): ctcccttatgcgactcctgc.
[0137] SEQ ID NO: 10 (LgtA-YZ-R): atgcggccgtgtacaatacg.
[0138] (b) The plasmid pRSFDuet-LgtA and the fragment amplified using LgtB as a template in step (1) were double-digested using Nde I restriction endonuclease and Pac I restriction endonuclease. The digested fragments were ligated using T4 ligase and transformed into Escherichia coli DH5α. Positive transformants were screened, verified, and sequenced to obtain plasmid pRSFDuet-LgtALgtB.
[0139] The amplification primer sequences for fragment LgtB are shown in SEQ ID NO:11~12.
[0140] SEQ ID NO: 11 (LgtB-F): ggaattccatatgcgtgtttttatcatcagcc.
[0141] SEQ ID NO: 12 (LgtB-R): ccttaattaattacacgaactgccagtatttc.
[0142] The amplification primer sequences used for verification and sequencing are shown in SEQ ID NO:13~14.
[0143] SEQ ID NO: 13 (LgtB-YZ-F): cgtattgtacacggccgcat.
[0144] SEQ ID NO: 14 (LgtB-YZ-R): gtgaccgtgtgcttctcaaatg.
[0145] (c) Using plasmid pRSFDuet-LgtALgtB as a template, the linearized fragment LgtALgtB was amplified by reverse PCR.
[0146] The reverse PCR amplification reaction program was as follows: 95℃ pre-denaturation for 5 min; 95℃ denaturation for 30 s, 54℃ annealing for 30 s, 72℃ extension for 3 min, for 34 cycles; 72℃ final extension for 5 min.
[0147] The reaction system for reverse PCR amplification was as follows: 1 µL Phanta DNA Polymerase, 25 µL 2× Phantabuffer, 1 µL dNTP mix, 2 µL Primer F (10 µM), 2 µL Primer R (10 µM), 1 µL TemplatecDNA, and 18 µL ddH2O.
[0148] The amplification primer sequences for fragment LgtALgtB are shown in SEQ ID NO:15~16.
[0149] SEQ ID NO: 15 (LgtALgtB-F): ggcagcagccatcaccatca.
[0150] SEQ ID NO: 16 (LgtALgtB-R): catggtatatctccttattaaagttaaac.
[0151] (d) The fragment pelB was amplified using pelB from step (1) as a template. The amplification primer sequences are shown in SEQ ID NO:17~18.
[0152] SEQ ID NO: 17 (pelB-F): aggagatataccatgaaatacctgctgccgacc.
[0153] SEQ ID NO: 18 (pelB-R): gtgatggctgctgccggccatcgccggctgggc.
[0154] The ligation product was transformed into *E. coli* DH5α using the homologous recombination linker fragment pelB and the linearized fragment LgtALgtB. Positive transformants were screened, validated, and sequenced. Plasmids from the positive transformants were extracted to obtain the recombinant plasmid pRSFDuet-pelB-LgtALgtB (its plasmid map is shown below). Figure 1 (As shown).
[0155] The homologous recombination ligation system consisted of 5 μL 2×ClonExpress Mix, 4 μL fragment pelB, and 1 μL linearized fragment LgtALgtB.
[0156] The primer sequences used for verification and sequencing are shown in SEQ ID NO:19~20.
[0157] SEQ ID NO: 19 (pelB-LgtAB-YZ-F): ctcccttatgcgactcctg.
[0158] SEQ ID NO: 20 (pelB-LgtAB-YZ-R): ggccatagccggctgagccg.
[0159] (3) Strain construction: The plasmid pRSFDuet-pelB-LgtALgtB was electroporated into E. coli BL21(DE3) chassis cells. Positive transformants were screened, verified and sequenced. The positive transformants were named pRSFDuet-pelB-LgtALgtB-BL21(DE3). Some terminators, promoters and donor organisms contained in the genome of the above recombinant strain are shown in Table 1.
[0160] The primer sequences used for verification and sequencing are shown in SEQ ID NO:19~20.
[0161] Table 1
[0162]
[0163] (4) Shaking test
[0164] (a) Primary seed culture activation: The recombinant strain pRSFDuet-pelB-LgtALgtB-BL21(DE3) screened in this example was inoculated into LB liquid medium containing 50 μg / mL kanamycin for activation culture to obtain the primary seed culture. The culture conditions were 37℃ and 180 rpm, and cultured until OD... 600The pH was 1.0–2.0. The LB liquid medium used for activation consisted of 5 g / L yeast extract, 10 g / L peptone, 10 g / L sodium chloride, and water at natural pH.
[0165] (b) Secondary seed culture activation: The primary seed culture was inoculated at a volume ratio of 1% into LB liquid medium containing 50 μg / mL kanamycin to obtain the secondary seed culture. The culture conditions were 37℃ and 180 rpm, and cultured until OD... 600 The pH was 1.0–2.0. The LB medium used for activation consisted of 5 g / L yeast extract, 10 g / L peptone, 10 g / L sodium chloride, and water at its natural pH.
[0166] (c) Fermentation culture: The above secondary seed culture was inoculated into DM fermentation medium at a volume ratio of 1% (30 mL system), and the culture conditions were 37℃ and 220 rpm. The composition of DM fermentation medium is shown in Table 2.
[0167] Table 2
[0168]
[0169] (d) Product content detection: Samples were taken after 70 h of fermentation, centrifuged (6000 rpm, 10 min) and the supernatant was collected for high performance liquid chromatography detection.
[0170] LNnT in fermentation broth samples was detected using a Bio-Rad column (Aminex® HPX-87H column, 7.8*300 mm, 9 μm) and a high-performance liquid chromatograph (LC-16, Shimadzu, Japan). The LNnT content in the samples was calculated using the external standard method. Specifically, the chromatographic conditions were as follows: mobile phase: 5 mmol / L sulfuric acid aqueous solution; flow rate: 0.5 mL / min; run time: 20 min; column temperature: 60℃.
[0171] Example 2: Construction of recombinant strain pRSFDuet-DsbA-LgtALgtB-BL21(DE3)
[0172] The method for constructing the recombinant strain in this embodiment is basically the same as that in Example 1, except that the construction steps of the recombinant plasmid are different. Specifically, the gene fragment encoding the synthesized pelB signal peptide protein is replaced with the gene fragment encoding the synthesized DsbA signal peptide protein (i.e., the DsbA fragment, nucleotide sequence as shown in SEQ ID NO:3); correspondingly, the primer sequences for verifying and screening the recombinant strain pRSFDuet-DsbA-LgtALgtB-BL21(DE3) are shown in SEQ ID NO:21~22.
[0173] SEQ ID NO:3
[0174] atgaaaaaaatttggctggcgctggcgggcctggtgctggcgtttagcgcgagcgcg.
[0175] SEQ ID NO:21 (DsbA-F)
[0176] taataaggagatataccatgaaaaaaatttggctggcg.
[0177] SEQ ID NO:22 (DsbA-R)
[0178] tgatggtgatggctgctgcccgcgctcgcgctaaacgc.
[0179] Example 3: Construction of recombinant strain pRSFDuet-OmpA-LgtALgtB-BL21(DE3)
[0180] The method for constructing the recombinant strain in this embodiment is basically the same as that in Example 1, except that the construction steps of the recombinant plasmid are different. Specifically, the gene fragment encoding the synthesized pelB signal peptide protein is replaced with the gene fragment encoding the synthesized OmpA signal peptide protein (i.e., the OmpA fragment, nucleotide sequence as shown in SEQ ID NO:4); correspondingly, the primer sequences for verifying and screening the recombinant strain pRSFDuet-OmpA-LgtALgtB-BL21(DE3) are shown in SEQ ID NO:23~24.
[0181] SEQ ID NO:4
[0182] atgaaaaaaaccgcgattgcgattgcggtggcgctggcgggctttgcgaccgtggcgcaggcg.
[0183] SEQ ID NO:23 (OmpA-F)
[0184] taataaggagatataccatgaaaaaaaccgcgattgc.
[0185] SEQ ID NO:24 (OmpA-R)
[0186] tgatggtgatggctgctgcccgcctgcgccacggtcgc.
[0187] Comparative Example 1: Construction of recombinant strain pRSFDuet-LgtALgtB-BL21(DE3)
[0188] The method for constructing recombinant strains in this comparative example is basically the same as that in Example 1, except that the construction steps of the recombinant plasmid and the recombinant strain are different. Specifically, the plasmid pRSFDuet-LgtALgtB was directly electroporated into E. coli BL21(DE3) chassis cells, positive transformants were screened and verified and sequenced to obtain the recombinant strain pRSFDuet-LgtALgtB-BL21(DE3).
[0189] Referring to the shake-flask verification method described in step (4) of Example 1, the content of lactose-N-neotetrasaccharide produced by the recombinant strains screened in Examples 1-3 and Comparative Example 1 after fermentation for 70 h was detected, and the results are shown in Table 3.
[0190] Table 3
[0191]
[0192] As shown in the table above, the recombinant strain constructed in Comparative Example 1, which lacks the protein-coding fragment of the Sec signal peptide, exhibits low efficiency in the fermentation production of lactose-N neotetrasaccharide. In contrast, the recombinant strains constructed in Examples 1-3 of this application, which contain the protein-coding fragment of the Sec signal peptide, show significantly increased fermentation yield when used for the production of lactose-N neotetrasaccharide. Furthermore, as demonstrated in Examples 1-3, compared to the DsbA and OmpA signal peptides, inserting a gene fragment encoding the pelB signal peptide into the genome of the recombinant strain can further enhance the fermentation yield of lactose-N neotetrasaccharide.
[0193] The technical features of the above embodiments can be combined in any way. For the sake of brevity, not all possible combinations of the technical features in the above embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.
[0194] The embodiments described above are merely illustrative of several implementation methods of this application, and while the descriptions are specific and detailed, they should not be construed as limiting the scope of the invention patent. It should be noted that those skilled in the art can make various modifications and improvements without departing from the concept of this application, and these all fall within the protection scope of this application. Therefore, the protection scope of this application should be determined by the appended claims.
Claims
1. A genetically engineered bacterium that produces lactose-N-neotetrasaccharide, characterized in that, The exogenous expression of the genetically engineered bacteria: (1) Sec signal peptide; and (2) Glycosyltransferases, including β-1,3-N-acetylglucosamine transferase and β-1,4-galactosyltransferase; The genetically engineered bacterium is Escherichia coli; The Sec signal peptide is linked to the N-terminus of the β-1,3-N-acetylglucosamine transferase, and the two are co-expressed. The Sec signal peptide is either the DsbA signal peptide or the pelB signal peptide.
2. The genetically engineered bacterium for producing lactose-N-neotetrasaccharide according to claim 1, characterized in that, One or more of the following conditions must be met: (1) The nucleotide sequence encoding the pelB signal peptide is shown in SEQ ID NO:1 or SEQ ID NO:2; (2) The nucleotide sequence encoding the DsbA signal peptide is shown in SEQ ID NO:
3.
3. The genetically engineered bacterium for producing lactose-N-neotetrasaccharide according to claim 1, characterized in that, The glycosyltransferase satisfies one or more of the following conditions: (1) The nucleotide sequence encoding β-1,3-N-acetylglucosamine transferase is shown in SEQ ID NO:5; and (2) The nucleotide sequence encoding β-1,4-galactosyltransferase is shown in SEQ ID NO:
6.
4. The genetically engineered bacterium for producing lactose-N-neotetrasaccharide according to claim 1, characterized in that, One or more of the wcaJ, lacZ, fucIK, nanA, nanK, nanE, and nanT genes in the genome of the genetically engineered bacteria are inactivated or deleted.
5. The genetically engineered bacterium for producing lactose-N-neotetrasaccharide according to claim 4, characterized in that, The wcaJ, lacZ, and fucIK genes in the genome of the genetically engineered bacteria are inactivated or deleted.
6. The method for constructing a genetically engineered bacterium for producing lactose-N-neotetrasaccharide as described in any one of claims 1 to 5, characterized in that, Includes the following steps: The nucleic acid fragment encoding the Sec signal peptide and the glycosyltransferase was introduced into the chassis cells to construct the genetically engineered bacteria.
7. A method for preparing lactose-N-neotetrasaccharide, characterized in that, Includes the following steps: The genetically engineered bacteria according to any one of claims 1 to 5 are fermented to prepare lactose-N-neotetrasaccharide.
8. A method for producing dairy products, characterized in that, Includes the following steps: Lactose-N-neotetrasaccharide was prepared using the preparation method described in claim 7; and, Dairy products are prepared using the lactose-N-neotetrasaccharide.
Citation Information
Patent Citations
Construction method and application of escherichia coli engineering strain with high yield of lactoyl-N-neotetraose
CN115851570A
Reduced pantothenic acid levels in fermentative production of oligosaccharides
CN118434879A
Genetically engineered bacterium for producing human milk oligosaccharide as well as construction method and application of genetically engineered bacterium
CN118667738A
Genetically engineered bacterium for producing lactose-N-neotetraose as well as construction method and application of genetically engineered bacterium
CN119736222A
Method for fermentation production of human milk oligosaccharide by cell synthesis method
CN120718980A
